Skip to content

Affiliation

University College London Hospitals NHS Foundation Trust

Country

United Kingdom

Current position
Jatinder Harchowal
has 22 years’ experience as a Chief Pharmacist and is currently in University College London Hospitals NHS Foundation Trust (UCLH). Prior to working in UCLH, Jatinder worked as Chief Pharmacist in Ealing Hospital, Brighton & Sussex University Hospitals, and The Royal Marsden. In March 2020, Jatinder was seconded as Director of Pharmacy for the Nightingale Hospital, leading the set up and running of a medicines optimisation service to help support the COVID-19 pandemic. Jatinder was also interim Chief Pharmacist for the North Central London Integrated Care System from October 2022-June 2023, helping to set up new governance processes for use of medicines across the newly formed integrated system. Jatinder was the Chair of the Royal Pharmaceutical Society’s Hospital Expert Advisory Group (HEAG) for 5 years from 2018-2023 and is an appointed member of the King’s Fund General Advisory Board. He is a Health Foundation Fellow and was awarded a Fellowship for the Royal Pharmaceutical Society in 2020. In October 2020, Jatinder was awarded an MBE in the Queen’s Birthday Honours for his work during the COVID-19 pandemic and services to the pharmaceutical profession. In May 2022, Jatinder was awarded the Guild of Healthcare Pharmacists Gold medal for achievements and contributions to the profession at a national level.

Education
Jatinder studied Pharmacy at the University of Bradford and qualified in 1991. After completing his Dilpoma in Clinical Pharmacy, Jatinder went to complete his Masters in Clinical Pharmacy in 1995, focusing on drug related admissions into hospital. He also completed his Diploma in Management Studies, before completing an MSc in Leadership and Quality Improvement in 2014 with Ashridge Business School. In addition, Jatinder is a qualified career coach and recently completed his IHI Improvement Advisor training.

Research area
Mr. Harchowal’s research interests have been in Renal Pharmacy Practice and the introduction of Biosimilars into practice.

Conflict of interest
None.